Drug patents opposed in 2021
Drug patents opposed in 2021 at the European Patent Office (EPO)
| Patent Number | Patent Title | Company | Recent Opposition Date | Recent Opposition By | Activity Alert |
|---|---|---|---|---|---|
| EP2729151B1 | Pharmaceutical Composition, Methods For Treating And Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
28 Dec, 2021
(Expiration: Jul, 2032)
|
GENERICS UK
(and 1 more)
| |
| EP3214058B1 | Magnesium Fluoride Sintered Compact For Neutron Moderator | UNIVERSITY OF TSUKUBA NUC |
28 Dec, 2021
(Expiration: May, 2034)
|
NIKKEI SANGYO
| |
| EP3277718B1 | Dosage Regimen For Anti-Mif Antibodies | BAXALTA GMBH |
24 Dec, 2021
(Expiration: Mar, 2036)
|
SCORPIO
| |
| EP3329018B1 | Methods For Treating Hepcidin-Mediated Disorders | MEDIMMUNE LTD |
24 Dec, 2021
(Expiration: Jul, 2036)
|
STRAWMAN
| |
| EP3484585B1 | Use Of Probiotics In The Treatment And/Or Prevention Of Atopic Dermatitis | BIONOU RESEARCH SL |
23 Dec, 2021
(Expiration: Jul, 2037)
|
CHR HANSEN
| |
| EP3200591B1 | Central Memory T Cells For Adoptive T Cell Therapy | CITY OF HOPE |
23 Dec, 2021
(Expiration: Sep, 2035)
|
PATENT BOUTIQUE
(and 1 more)
| |
| EP3218406B1 | Binding Molecules Specific For Cd73 And Uses Thereof | MEDIMMUNE LTD |
23 Dec, 2021
(Expiration: Nov, 2035)
|
ROTH
(and 1 more)
| |
| EP3288561B1 | Methods And Pharmaceutical Compositions Comprising A Sglt2 Inhibitor For Treating Or Improving Erectile Dysfunction | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
23 Dec, 2021
(Expiration: Apr, 2036)
|
SANDOZ
| |
| EP2234617B1 | Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters | JANSSEN PHARMACEUTICA NV |
22 Dec, 2021
(Expiration: Dec, 2028)
|
HOFFMANN EITLE
(and 19 more)
| |
| EP2985027B1 | Nasal Composition Comprising Mixture Of Hyaluronic Acids And Saline Solution | CHURCH AND DWIGHT CO INC |
22 Dec, 2021
(Expiration: Aug, 2034)
|
PATENTANWALT DIPL ING DIETZE
| |
| EP3246017B1 | Stable Liquid Formulation Of Amg 416 Hcl (Etelcalcetide) | AMGEN INC |
22 Dec, 2021
(Expiration: Jun, 2034)
|
STADA ARZNEIMITTEL
(and 3 more)
| |
| EP3256569B2 | Alveolar-Like Macrophages And Method Of Generating Same | HOSPITAL FOR SICK CHILDREN HSC |
22 Dec, 2021
(Expiration: Feb, 2036)
|
STRAWMAN
| |
| EP2753310B1 | Formulation For The Controlled Release Of One Or Several Substances In The Digestive Tract Of A Mammal | INDIVIDUAL |
21 Dec, 2021
(Expiration: Sep, 2032)
|
ELKINGTON AND FIFE
| |
| EP3173071B1 | Maropitant Formulation | LE VET BV |
20 Dec, 2021
(Expiration: Nov, 2036)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
(and 1 more)
| |
| EP2512436B1 | Conditioning Composition For Hair | KAO GERMANY GMBH |
17 Dec, 2021
(Expiration: Dec, 2030)
|
HENKEL
| |
| EP2421578B1 | Assembly, Device Kit And Method For Preparing Platelet-Rich Plasma (Prp) | INDIVIDUAL |
17 Dec, 2021
(Expiration: Apr, 2030)
|
REGEN LAB
| |
| EP3377103B1 | Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells | REVITOPE LTD |
16 Dec, 2021
(Expiration: Nov, 2036)
|
CHERRY BIOLABS
(and 1 more)
| |
| EP3134084B1 | Method Of Treating Lung Adenocarcinoma | EXELIXIS INC |
16 Dec, 2021
(Expiration: Apr, 2035)
|
GENERICS UK
| |
| EP2988830B1 | Composition For Straightening Keratin Fibres, Comprising A Urea And/Or A Urea Derivative And A Nonionic, Cationic, Amphoteric Or Anionic Associative Polymeric Thickener, Process And Use Thereof | LOREAL SA |
15 Dec, 2021
(Expiration: Apr, 2034)
|
BEIERSDORF
| |
| EP3554461B1 | Cosmetic Composition Comprising Solid Fatty Substances And A Gelling Polymer | LOREAL SA |
15 Dec, 2021
(Expiration: Dec, 2037)
|
HENKEL
(and 2 more)
| |
| EP3318255B1 | Compositions And Methods For Lowering Triglycerides Without Raising Ldl-C Levels In A Subject On Concomitant Statin Therapy | AMARIN PHARMACEUTICALS IRELAND LTD |
10 Dec, 2021
(Expiration: Jun, 2030)
|
COOKE
(and 2 more)
| |
| EP2516330B1 | Particulate Titanium Dioxide | CRODA INTERNATIONAL PLC |
10 Dec, 2021
(Expiration: Dec, 2030)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3313874B1 | Masking Chimeric Antigen Receptor T Cells For Tumor-Specific Activation | UNIVERSITY OF SOUTHERN CALIFORNIA USC |
10 Dec, 2021
(Expiration: Jun, 2036)
|
JAMES POOLE
| |
| EP3604339B1 | Therapeutic Antibodies Against Ror-1 Protein And Methods For Use Of Same | UNIVERSITY OF CALIFORNIA |
10 Dec, 2021
(Expiration: Jan, 2032)
|
JG OPPOSITIONS
| |
| EP2806914B1 | A System And Method For Obtaining A Cellular Sample Enriched With Defined Cells Such As Platelet Rich Plasma(Prp) | ESTAR TECHNOLOGIES LTD |
10 Dec, 2021
(Expiration: Jan, 2033)
|
REGEN LAB
| |
| EP3200605B1 | Method For Producing Biomass Which Has A High Exopolysaccharide Content | EVONIK OPERATIONS GMBH |
09 Dec, 2021
(Expiration: Oct, 2035)
|
ABEL & IMRAY
| |
| EP3200602B1 | Process For Producing A Pufa-Containing Biomass Which Has High Cell Stability | EVONIK OPERATIONS GMBH |
09 Dec, 2021
(Expiration: Sep, 2035)
|
ABEL & IMRAY
| |
| EP3061454B1 | Parasiticidal Oral Veterinary Compositions Comprising Systemically-Acting Active Agents, Methods And Uses Thereof | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
09 Dec, 2021
(Expiration: Jan, 2033)
|
KRKA
(and 1 more)
| |
| EP3562465B2 | Novel Antioxidants For Cosmetics And Pharmaceutical Compositions Containing Glycerol Alkyl Ethers | SACHEM INC |
08 Dec, 2021
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP3288980B1 | Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody | BRISTOL MYERS SQUIBB CO |
08 Dec, 2021
(Expiration: Apr, 2036)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
(and 4 more)
| |
| EP3139904B1 | Formulation Of Fat-Soluble Vitamin | BASF SE |
03 Dec, 2021
(Expiration: May, 2035)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3378486B1 | Stabilized Antibody-Containing Liquid Formulations | CHUGAI PHARMACEUTICAL CO LTD |
03 Dec, 2021
(Expiration: Jan, 2031)
|
ELKINGTON AND FIFE
(and 4 more)
| |
| EP3592432B1 | Gardenia Extract For Keratin Fibre Dyeing | PIERRE FABRE DERMO COSMETIQUE SA |
03 Dec, 2021
(Expiration: Mar, 2038)
|
HENKEL
| |
| EP3153155B1 | Refillable Drug Delivery Devices And Methods Of Use Thereof | HARVARD COLLEGE |
03 Dec, 2021
(Expiration: Sep, 2036)
|
JAMES POOLE
| |
| EP2968155B1 | Tofacitinib Oral Sustained Release Dosage Forms | PFIZER INC |
03 Dec, 2021
(Expiration: Mar, 2034)
|
STADA ARZNEIMITTEL
(and 5 more)
| |
| EP3028691B1 | Ceramide Dispersion Composition | FUJIFILM CORP |
02 Dec, 2021
(Expiration: Jun, 2034)
|
EVONIK INDUSTRIES
(and 1 more)
| |
| EP2797574B1 | Oxidative Dyeing Composition | KAO GERMANY GMBH |
02 Dec, 2021
(Expiration: Dec, 2032)
|
HENKEL
| |
| EP3398444B1 | Method To Convert Insects Or Worms Into Nutrient Streams And Compositions Obtained Thereby | BUEHLER INSECT TECHNOLOGY SOLUTIONS AG |
02 Dec, 2021
(Expiration: Jun, 2033)
|
YNSECT
(and 2 more)
| |
| EP3197493B1 | Methods Of Reversing Cachexia And Prolonging Survival Comprising Administering A Gdf15 Modulator And An Anti-Cancer Agent | AVEO PHARMACEUTICALS INC |
29 Nov, 2021
(Expiration: Sep, 2035)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP3484437B1 | Dentifrice Including Zinc And Blue Dye Or Pigment | COLGATE PALMOLIVE CO |
26 Nov, 2021
(Expiration: Aug, 2036)
|
UNILEVER UNILEVER
| |
| EP3405495B1 | Neutralization Of Inhibitory Pathways In Lymphocytes | INNATE PHARMA SAS |
24 Nov, 2021
(Expiration: Jan, 2037)
|
HIBERG PS
| |
| EP3442491B1 | Surface-Modified Effect Pigment And Nail Varnish Composition | ECKART GMBH |
24 Nov, 2021
(Expiration: Apr, 2037)
|
SCHLENK METALLIC PIGMENTS
| |
| EP3293202B2 | Anti Human Interleukin-1 Receptor Accessory Protein (Il1Rap) Antibodies And Uses Thereof | CANTARGIA AB |
24 Nov, 2021
(Expiration: Mar, 2035)
|
ZWICKER SCHNAPPAUF & PARTNER PATENTANWLTE PARTG MBB
(and 2 more)
| |
| EP3197427B1 | O/W Emulsions | DSM IP ASSETS BV |
23 Nov, 2021
(Expiration: Sep, 2035)
|
DALLI WERKE
| |
| EP3450434B1 | Deuterated Derivatives Of Ruxolitinib | CONCERT PHARMACEUTICALS INC |
23 Nov, 2021
(Expiration: Jun, 2033)
|
INCYTE
| |
| EP3549601B1 | Non-Lipidated Variants Of Neisseria Meningitidis Orf2086 Antigens | WYETH LLC |
23 Nov, 2021
(Expiration: Sep, 2031)
|
JG OPPOSITIONS
| |
| EP2275132B1 | Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Them | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
22 Nov, 2021
(Expiration: Dec, 2026)
|
ELANCO
(and 2 more)
| |
| EP2858679B1 | Pulmonary Delivery Of Mrna To Non-Lung Target Cells | ETHRIS GMBH |
22 Nov, 2021
(Expiration: Jun, 2033)
|
FRKELLY
| |
| EP3329909B1 | Fenfluramine For Use In The Treatment Of Dravet Syndrome | UNIVERSITY HOSPITAL ANTWERP |
22 Nov, 2021
(Expiration: May, 2034)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
(and 1 more)
| |
| EP3134123B1 | Il-2Rbeta-Selective Agonists In Combination With An Anti-Ctla-4 Antibody Or An An Anti-Pd-1 Antibody | NEKTAR THERAPEUTICS INDIA PVT LTD |
17 Nov, 2021
(Expiration: Feb, 2035)
|
GREINER
| |
| EP3544976B1 | N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)-Phenyl]-Acetamide Free Base Hemihydrate, Methods Of Manufacture And Uses Thereof | AICURIS GMBH AND CO KG |
17 Nov, 2021
(Expiration: Nov, 2037)
|
INNOVATIVE MOLECULES
| |
| EP3177645B1 | Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer | LINDIS BIOTECH GMBH |
17 Nov, 2021
(Expiration: Aug, 2035)
|
MORPHOSYS
(and 9 more)
| |
| EP3331894B1 | Nicotinamide Mononucleotide Derivatives And Their Uses | METRO INTERNATIONAL BIOTECH LLC |
17 Nov, 2021
(Expiration: Aug, 2036)
|
PLASSERAUD
| |
| EP3071206B1 | Gastrin Antagonists (Eg Yf476, Netazepide) For Treatment And Prevention Of Osteoporosis | CL BIOSCIENCES LLC |
17 Nov, 2021
(Expiration: Nov, 2034)
|
TRIO MEDICINES
| |
| EP3019198B1 | Compositions And Methods For Improving Rebaudioside M Solubility | PURECIRCLE SDN BHD |
16 Nov, 2021
(Expiration: Jul, 2034)
|
EISENFHR SPEISER
(and 1 more)
| |
| EP3600486B1 | Carbohydrate Composition For Dialysis | OPTERION HEALTH AG |
16 Nov, 2021
(Expiration: Mar, 2038)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP3461472B2 | Sensitive Skin Cleanser With Enhanced Cleaning Effect | PETER GREVEN PHYSIODERM GMBH |
16 Nov, 2021
(Expiration: Oct, 2038)
|
HENKEL
| |
| EP3320902B1 | Methods For Treating Diseases Using Isoindoline Compounds | AMGEN EUROPE GMBH |
16 Nov, 2021
(Expiration: Mar, 2032)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3651862B1 | High Glycerol Composition Comprising Blends Of Alkyl Isethionate And Alkyl Taurate | UNILEVER PLC |
15 Nov, 2021
(Expiration: May, 2038)
|
HENKEL
| |
| EP3515400B1 | Compositions Comprising Specific Surfactants And High Levels Of Glycerin | UNILEVER PLC |
12 Nov, 2021
(Expiration: Sep, 2037)
|
HENKEL
| |
| EP3401335B1 | Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof | GENENTECH INC |
08 Nov, 2021
(Expiration: Jan, 2029)
|
HEXAL
(and 4 more)
| |
| EP3030214B2 | Alcoholic Sunscreen Gel | BEIERSDORF AG |
05 Nov, 2021
(Expiration: Jun, 2034)
|
HENKEL
(and 1 more)
| |
| EP3616680B1 | Compound Containing Basic Dye And Amino Acid, Hair Dying Dye, And Hair Dying Composition | HODOGAYA CHEMICAL CO LTD |
05 Nov, 2021
(Expiration: Aug, 2039)
|
HENKEL
| |
| EP3102186B1 | Donepezil Compositions And Method Of Treating Alzheimer'S Disease | FOREST LABORATORIES HOLDINGS LTD |
27 Oct, 2021
(Expiration: Feb, 2035)
|
BLLE DR
| |
| EP2944306B1 | Vegf Antagonist Formulations Suitable For Intravitreal Administration | REGENERON PHARMACEUTICALS INC |
27 Oct, 2021
(Expiration: Jun, 2027)
|
BOULT WADE TENNANT
(and 2 more)
| |
| EP3169308B1 | Suspension Compositions Of Cyclosporin A For Subconjunctival And Periocular Injection | ALLERGAN INC |
27 Oct, 2021
(Expiration: Jul, 2035)
|
GILL JENNINGS & EVERY
| |
| EP3525781B2 | Composition Comprising Epa And Dha For An Enhanced Efficacy Of Anticancer Agents | FRESENIUS KABI DEUTSCHLAND GMBH |
27 Oct, 2021
(Expiration: Oct, 2037)
|
NUTRICIA
| |
| EP2993999B1 | Nicotine Salt Formulations For Aerosol Devices And Methods Thereof | JUUL LABS INC |
27 Oct, 2021
(Expiration: May, 2034)
|
PHILIP MORRIS PRODUCTS
(and 2 more)
| |
| EP3220752B1 | Use Of Whey Protein Micelles And Polysaccharides For Improving Insulin Profile | SOCIETE DES PRODUITS NESTLE SA |
26 Oct, 2021
(Expiration: Nov, 2035)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP3283179B1 | Solid Skin Care Emulsion Comprising Solid And Liquid Lipids | BEIERSDORF AG |
26 Oct, 2021
(Expiration: Mar, 2036)
|
HENKEL
| |
| EP3082858B1 | Adrenomedullin Binder For Use In Therapy Of Cancer | ANGIOBIOMED GMBH |
26 Oct, 2021
(Expiration: Dec, 2034)
|
SCHIWECK WEINZIERL KOCH PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3215171B1 | Enteral Nutrition Composition | EVEN SANTE INDUSTRIE SAS |
25 Oct, 2021
(Expiration: Nov, 2035)
|
NUTRICIA
(and 1 more)
| |
| EP2952177B1 | Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators | NOVARTIS AG |
20 Oct, 2021
(Expiration: Oct, 2028)
|
ACCORD HEALTHCARE
| |
| EP3370770B1 | Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses | JANSSEN BIOTECH INC |
20 Oct, 2021
(Expiration: Nov, 2036)
|
BREUER
(and 2 more)
| |
| EP3402455B1 | Cosmetic Preparations Containing Benzethonium Chloride And Diols | BEIERSDORF AG |
20 Oct, 2021
(Expiration: Dec, 2036)
|
LORAL
| |
| EP3616720B1 | Pharmaceutical Composition For Cancer Treatment | OSAKA UNIVERSITY NUC |
14 Oct, 2021
(Expiration: Mar, 2038)
|
KNIG SZYNKA TILMANN VON RENESSE
(and 9 more)
| |
| EP3102208B1 | Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde | GLOBAL BLOOD THERAPEUTICS INC |
13 Oct, 2021
(Expiration: Feb, 2035)
|
BLLE DR
| |
| EP3393441B1 | Dyeing Composition Comprising A Direct Dye Of Triarylmethane Structure, And A Silicone | LOREAL SA |
13 Oct, 2021
(Expiration: Dec, 2036)
|
HENKEL
| |
| EP3310349B1 | Compositions And Methods For Enhancing Neurogenesis In Animals | SOCIETE DES PRODUITS NESTLE SA |
13 Oct, 2021
(Expiration: Jun, 2036)
|
NUTRICIA
(and 1 more)
| |
| EP3113756B2 | Abrasive Skin Cleaning Products I | BEIERSDORF AG |
11 Oct, 2021
(Expiration: Feb, 2035)
|
HENKEL
| |
| EP3322731B1 | Method Of Treating Cancer Using Immune Checkpoint Inhibitor | BRISTOL MYERS SQUIBB CO |
07 Oct, 2021
(Expiration: Jul, 2036)
|
REGENERON PHARMACEUTICALS
(and 8 more)
| |
| EP2872171B1 | Toxicity Management For Anti-Tumor Activity Of Cars | CHILDRENS HOSPITAL OF PHILADELPHIA CHOP |
06 Oct, 2021
(Expiration: Jul, 2033)
|
GEDEON RICHTER PHARMA
(and 3 more)
| |
| EP3031907B1 | Materials And Methods To Enhance Hematopoietic Stem Cells Engraftment Procedures | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP |
06 Oct, 2021
(Expiration: Nov, 2029)
|
JAMES POOLE
| |
| EP3111942B1 | Compositions For Use In The Prevention Or Treatment Of Urt Infections In Infants Or Young Children At Risk | SOCIETE DES PRODUITS NESTLE SA |
06 Oct, 2021
(Expiration: Nov, 2034)
|
NUTRICIA
| |
| EP3068404B1 | Compositions For Use In The Prevention Or Treatment Of Urt Infections In Infants Or Young Children At Risk | SOCIETE DES PRODUITS NESTLE SA |
06 Oct, 2021
(Expiration: Nov, 2034)
|
NUTRICIA
| |
| EP3322487B1 | Magnolia Bark Extract As A Hydrophobic Ligand For Preferential Removal Of Gram Negative Bacteria From The Oral Cavity | WM WRIGLEY JR CO |
06 Oct, 2021
(Expiration: Jul, 2036)
|
PERFETTI VAN MELLE
| |
| EP3377110B1 | Nanoparticles Based On Optionally Alkoxylated Poly(Alkyl Cyanoacrylates) Having A Defined Degree Of Polymerization | ABBVIE DEUTSCHLAND GMBH AND CO KG |
06 Oct, 2021
(Expiration: Oct, 2036)
|
SINTEF TTO
| |
| EP3550985B1 | Nutritional Composition For Improving Cell Membranes | NUTRICIA NV |
06 Oct, 2021
(Expiration: Dec, 2037)
|
SOCIT DES PRODUITS NESTL
| |
| EP2359701B1 | Composition For Improving Membrane Composition And Functioning Of Cells | NUTRICIA NV |
06 Oct, 2021
(Expiration: Dec, 2026)
|
STRAWMAN
(and 3 more)
| |
| EP3377049B1 | Crystalline Forms Of Tapentadol Salts And Process For Preparation Thereof | MSN LABORATORIES PVT LTD |
06 Oct, 2021
(Expiration: Nov, 2036)
|
URQUHART DYKES & LORD
| |
| EP2345410B1 | Controlled Release Pharmaceutical Composition | ASTELLAS PHARMA INC |
30 Sep, 2021
(Expiration: Sep, 2029)
|
BRAND MURRAY FULLER
(and 5 more)
| |
| EP2874507B1 | Aqueous Transparent Oil-In-Water Emulsion Comprising An Emulsified Carotenoid | BASF SE |
30 Sep, 2021
(Expiration: Jul, 2033)
|
CHR HANSEN NATURAL COLORS
| |
| EP3453686B1 | Lithium Silicate Glass Ceramic And Glass With Zro2 Content | IVOCLAR VIVADENT AG |
30 Sep, 2021
(Expiration: Apr, 2031)
|
DENTSPLY SIRONA
| |
| EP3547992B1 | Mixtures Comprising A Phenyl Alkanol And A Linear Alcohol With 8 To 12 Carbon Atoms | SYMRISE AG |
30 Sep, 2021
(Expiration: Nov, 2037)
|
FIRMENICH
| |
| EP3478322B1 | Methods And Compounds For The Treatment Or Prevention Of Severe Influenza | HVIVO SERVICES LTD |
30 Sep, 2021
(Expiration: Jun, 2037)
|
GILL JENNINGS & EVERY
| |
| EP3359561B1 | Modulators Of Complement Function | INDIVIDUAL |
29 Sep, 2021
(Expiration: Dec, 2036)
|
ALGEMEEN OCTROOI EN MERKENBUREAU
| |
| EP3389618B1 | Process For Treating Keratin Fibres Using An Aqueous Composition Comprising A Combination Of Particular Alkoxysilanes | LOREAL SA |
29 Sep, 2021
(Expiration: Dec, 2036)
|
HENKEL
| |
| EP3246044B2 | Stable Formulations Of Neisseria Meningitidis Rlp2086 Antigens | WYETH LLC |
29 Sep, 2021
(Expiration: Aug, 2031)
|
SANOFI PASTEUR
| |
| EP2925324B1 | Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of Schizophrenia | RICHTER GEDEON NYRT |
29 Sep, 2021
(Expiration: Nov, 2033)
|
WITTKOPP
(and 1 more)
| |
| EP3366283B1 | Direct Compression Formulation And Process | NOVARTIS AG |
28 Sep, 2021
(Expiration: Jan, 2025)
|
COOKE
(and 5 more)
| |
| EP3503867B1 | Transparent Cosmetic Cleaning Compositions Having An Improved Rheology Profile | HENKEL AG AND CO KGAA |
24 Sep, 2021
(Expiration: Jul, 2037)
|
CRODA
(and 1 more)
| |
| EP3240612B1 | Methods Of Treating Retinal Diseases | CELL CURE NEUROSCIENCES LTD |
23 Sep, 2021
(Expiration: Apr, 2035)
|
JAMES POOLE
(and 1 more)
| |
| EP3335736B1 | Heterodimers Of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS INC |
23 Sep, 2021
(Expiration: Nov, 2027)
|
LEWIS SILKIN
(and 2 more)
| |
| EP2729126B1 | Liposomes Having Useful N:P Ratio For Delivery Of Rna Molecules | GLAXOSMITHKLINE BIOLOGICALS SA |
23 Sep, 2021
(Expiration: Jul, 2032)
|
MLLER
(and 3 more)
| |
| EP3216463B1 | Solid Preparation Containing Alkyl Cellulose And Method For Producing The Same | SHIN ETSU CHEMICAL CO LTD |
22 Sep, 2021
(Expiration: Feb, 2037)
|
DUPONT NUTRITION BIOSCIENCES APS
| |
| EP3622946B2 | Cosmetic Hair Composition Made Of Aloe Vera And Coconut Oil And Method For Preparing Same | LABORATOIRES LEA SAS |
21 Sep, 2021
(Expiration: Sep, 2039)
|
HENKEL
| |
| EP3522921B1 | Prevention Of Allergy | ASIT BIOTECH SA |
21 Sep, 2021
(Expiration: Oct, 2037)
|
NUTRICIA
| |
| EP3177150B1 | A Combination Of Vitamin D And Zinc And Its Use | SOCIETE DES PRODUITS NESTLE SA |
20 Sep, 2021
(Expiration: Aug, 2035)
|
ABBOTT LABORATORIES
(and 2 more)
| |
| EP3215231B1 | Capsule Composition | GIVAUDAN SA |
16 Sep, 2021
(Expiration: Oct, 2035)
|
THE PROCTER & GAMBLE
(and 1 more)
| |
| EP3411057B2 | High Caloric, High Protein Nutritional Formula Comprising Collagen | FRESENIUS KABI DEUTSCHLAND GMBH |
15 Sep, 2021
(Expiration: Feb, 2037)
|
NUTRICIA
| |
| EP2545939B1 | Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring | BIOMARIN PHARMACEUTICAL INC |
14 Sep, 2021
(Expiration: Apr, 2028)
|
STADA ARZNEIMITTEL
(and 4 more)
| |
| EP3209295B2 | Methods Of Treating Ocular Conditions | OYSTER POINT PHARMA INC |
09 Sep, 2021
(Expiration: Oct, 2035)
|
BECK GREENER
| |
| EP3256573B1 | Recombinant Adeno-Associated Virus Particle Purification With Multiple-Step Anion Exchange Chromatography | UNIVERSITE DE NANTES |
09 Sep, 2021
(Expiration: Feb, 2036)
|
D YOUNG
| |
| EP3103469B1 | Cns Delivery Of Therapeutic Agents | SHIRE HUMAN GENETICS THERAPIES INC |
09 Sep, 2021
(Expiration: Jun, 2031)
|
GREEN CROSS
| |
| EP3337467B1 | Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment | IPSEN BIOPHARM LTD |
09 Sep, 2021
(Expiration: Aug, 2036)
|
SANDOZ
| |
| EP3345625B1 | Pharmaceutical Composition And Administrations Thereof | VERTEX PHARMACEUTICALS INC |
09 Sep, 2021
(Expiration: Aug, 2029)
|
STADA ARZNEIMITTEL
(and 2 more)
| |
| EP2356914B1 | Composition For Improving Membrane Composition And Functioning Of Cells | NUTRICIA NV |
06 Sep, 2021
(Expiration: Dec, 2026)
|
ABBOTT LABORATORIES
(and 1 more)
| |
| EP3363433B1 | Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy | AMARIN PHARMACEUTICALS IRELAND LTD |
03 Sep, 2021
(Expiration: Jun, 2033)
|
ELKINGTON AND FIFE
(and 2 more)
| |
| EP2734217B1 | Product For The Parenteral Nutrition Of Obese Intensive-Care Patients | FRESENIUS KABI DEUTSCHLAND GMBH |
02 Sep, 2021
(Expiration: Jul, 2032)
|
B BRAUN MELSUNGEN
| |
| EP3204022B1 | Placenta-Derived Adherent Cell Exosomes And Uses Thereof | CELULARITY INC |
02 Sep, 2021
(Expiration: Oct, 2035)
|
D YOUNG
| |
| EP3172209B1 | Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide | NOVARTIS AG |
01 Sep, 2021
(Expiration: Jul, 2035)
|
D YOUNG
| |
| EP3275424B1 | Composition To Reduce The Drying Time Of Keratin Fibers, Method And Use Thereof | KAO GERMANY GMBH |
01 Sep, 2021
(Expiration: Jul, 2036)
|
HENKEL
| |
| EP3400943B1 | Compounds For Use In The Treatment Of Erbb2+ Brain Cancer | ARRAY BIOPHARMA INC |
01 Sep, 2021
(Expiration: Mar, 2033)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3437513B1 | Nonwoven Sheet For Facial Mask | KOLON INDUSTRIES INC |
31 Aug, 2021
(Expiration: Apr, 2037)
|
CARL FREUDENBERG
| |
| EP3256574B1 | Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification Step | UNIVERSITE DE NANTES |
25 Aug, 2021
(Expiration: Feb, 2036)
|
J A KEMP
(and 6 more)
| |
| EP3154567B1 | Expansion Of Lymphocytes With A Cytokine Composition For Active Cellular Immunotherapy | POLYBIOCEPT GMBH |
25 Aug, 2021
(Expiration: Jun, 2035)
|
MARGARET DIXON
(and 1 more)
| |
| EP3482770B1 | Immunogenic Compositions | GLAXOSMITHKLINE BIOLOGICALS SA |
25 Aug, 2021
(Expiration: Oct, 2033)
|
PFIZER
| |
| EP3226842B1 | Anticancer Compositions | ARAGON PHARMACEUTICALS INC |
24 Aug, 2021
(Expiration: Dec, 2035)
|
ALFRED E TIEFENBACHER
(and 1 more)
| |
| EP3079714B1 | Long Lasting Effect Of New Botulinum Toxin Formulations | MEDY TOX INC |
24 Aug, 2021
(Expiration: Dec, 2034)
|
GALDERMA HOLDING
| |
| EP3228315B1 | Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains | AMGEN RESEARCH MUNICH GMBH |
24 Aug, 2021
(Expiration: Oct, 2031)
|
JAMES POOLE
(and 1 more)
| |
| EP3551181B1 | Treatment Comprising Oral Or Gastric Administration Of Edaravone | TREEWAY TW001 BV |
18 Aug, 2021
(Expiration: Jan, 2038)
|
BARDEHLE PAGENBERG PARTNERSCHAFT MBB PATENTANWLTE
| |
| EP3659594B1 | A Sterile Solution With An Application Injector Comprising A Medical Agent And Method For Producing Same | INDIVIDUAL |
18 Aug, 2021
(Expiration: Nov, 2038)
|
HEPP WENGER RYFFEL
| |
| EP3461484B9 | Combination Therapy | AERIE PHARMACEUTICALS INC |
18 Aug, 2021
(Expiration: Mar, 2034)
|
ISARPATENT PATENT UND RECHTSANWLTE BARTH CHARLES HASSA PECKMANN UND PARTNER MBB
(and 2 more)
| |
| EP3099333B8 | Bag3 As A Target For Therapy Of Heart Failure | TEMPLE UNIVERSITY OF COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
18 Aug, 2021
(Expiration: Jan, 2035)
|
JG OPPOSITIONS
| |
| EP3019185B1 | Combination Treatment For Atopic Dermatitis | MICREOS HUMAN HEALTH BV |
18 Aug, 2021
(Expiration: Jul, 2034)
|
SONN PATENTANWLTE
| |
| EP3307877B1 | Method To Treat Cancer With Engineered T-Cells | LENTIGEN TECHNOLOGY INC |
17 Aug, 2021
(Expiration: Jun, 2036)
|
DICK
| |
| EP3372238B1 | Insulin Formulations For Rapid Uptake | ELI LILLY AND CO |
16 Aug, 2021
(Expiration: Mar, 2030)
|
SAGITTARIUS CONSULTANTS
(and 1 more)
| |
| EP3137060B2 | Extended Release Suspension Compositions | SUN PHARMACEUTICAL INDUSTRIES LTD |
11 Aug, 2021
(Expiration: May, 2035)
|
RECKITT BENCKISER HEALTH
| |
| EP3058988B1 | Composition For Providing A Film On Keratin Fibres | NOXELL CORP |
10 Aug, 2021
(Expiration: Feb, 2036)
|
HENKEL
| |
| EP3461474B1 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD |
09 Aug, 2021
(Expiration: Aug, 2031)
|
HGF
(and 3 more)
| |
| EP3656869B1 | Engraftment Of Stem Cells With A Combination Of An Agent That Targets Stem Cells And Modulation Of Immunoregulatory Signaling | LELAND STANFORD JUNIOR UNIVERSITY |
09 Aug, 2021
(Expiration: Aug, 2035)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP3355701B1 | Liquid Nutritional Composition Comprising Micellar Casein And Hydrolysed Whey Protein | FRIESLANDCAMPINA NEDERLAND BV |
04 Aug, 2021
(Expiration: Sep, 2036)
|
ARLA FOODS AMBA
(and 2 more)
| |
| EP3515451B2 | Pharmaceutical Composition | MEXICHEM FLUOR SA DE CV |
04 Aug, 2021
(Expiration: Sep, 2037)
|
BECK GREENER
| |
| EP3400291B2 | Engineered Virus | REPLIMUNE LTD |
04 Aug, 2021
(Expiration: Jan, 2037)
|
STRAWMAN
(and 1 more)
| |
| EP2729188B1 | Compressed Gas Aerosols With Enhanced Intensity And Longevity Of Actives | SC JOHNSON AND SON INC |
04 Aug, 2021
(Expiration: Jul, 2032)
|
THE PROCTER & GAMBLE
| |
| EP3049073B1 | Compositions And Method For Destabilizing, Altering, And Dispersing Biofilms | UNIVERSITY OF NEWCASTLE, THE |
03 Aug, 2021
(Expiration: Sep, 2034)
|
COLGATE PALMOLIVE
| |
| EP3449250B1 | Methods And Compositions For Resolving Components Of A Virus Preparation | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
03 Aug, 2021
(Expiration: Apr, 2037)
|
DEFINITION
| |
| EP3687994B1 | Gadolinium Bearing Pcta-Based Contrast Agents | BRACCO IMAGING SPA |
02 Aug, 2021
(Expiration: Aug, 2039)
|
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP2575771B1 | Composition Comprising Biodegradable Polymers For Use In A Cosmetic Composition | MICRO POWDERS INC |
02 Aug, 2021
(Expiration: May, 2031)
|
ECKART
| |
| EP3565521B2 | O/W Emulsion Comprising A C16-C30 Fatty Alcohol, An Anionic Surfactant, An Oil, A Wax And A Hydrophilic Solvent | LOREAL SA |
02 Aug, 2021
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP3275438B2 | Methods Of Preventing Cardiovascular Events In Residual Risk Dyslipidemic Populations | KOWA CO LTD |
28 Jul, 2021
(Expiration: Jul, 2037)
|
BLLE DR
| |
| EP2818055B1 | High Energy Liquid Enteral Nutritional Composition | NUTRICIA NV |
28 Jul, 2021
(Expiration: Dec, 2028)
|
EVEN SANTE INDUSTRIE
(and 3 more)
| |
| EP3036256B1 | Modulation Of Tumor Immunity | MERCK SHARP AND DOHME LLC |
28 Jul, 2021
(Expiration: Aug, 2034)
|
PAJARO
(and 1 more)
| |
| EP3148576B8 | Vaccine Composition Against Streptococcus Suis Infection | CEVA SANTE ANIMALE SA |
27 Jul, 2021
(Expiration: May, 2035)
|
INTERVET
| |
| EP2820138B1 | Retroviral Transduction Using Poloxamers | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH |
27 Jul, 2021
(Expiration: Feb, 2033)
|
KNIG SZYNKA TILMANN VON RENESSE
| |
| EP1962797B2 | Powder Compositions For Inhalation | JAGOTEC AG |
22 Jul, 2021
(Expiration: Dec, 2026)
|
AERA
(and 1 more)
| |
| EP2897923B1 | Coloring Of Zirconia Ceramics | 3M INNOVATIVE PROPERTIES CO |
21 Jul, 2021
(Expiration: Sep, 2033)
|
IVOCLAR VIVADENT
| |
| EP3448370B2 | Composition For The Treatment Of Polycystic Ovary Syndrome | SOCHIM INTERNATIONAL SPA |
21 Jul, 2021
(Expiration: Apr, 2037)
|
LOLI PHARMA
| |
| EP3259029B1 | Medium Chain Fatty Acids And Their Triglycerides For Treating Anxiety | SOCIETE DES PRODUITS NESTLE SA |
21 Jul, 2021
(Expiration: Feb, 2036)
|
NUTRICIA
| |
| EP3512486B2 | Blue Powder And Use Thereof In Cosmetics | LOREAL SA |
20 Jul, 2021
(Expiration: Sep, 2037)
|
HENKEL
| |
| EP2689010B1 | Method And Compositions For Cellular Immunotherapy | FRED HUTCHINSON CANCER RESEARCH CENTER |
20 Jul, 2021
(Expiration: Mar, 2032)
|
KNIG SZYNKA TILMANN VON RENESSE
| |
| EP3007711B1 | A Dosing Regime And Formulations For Type B Adenoviruses | PSIOXUS THERAPEUTICS LTD |
19 Jul, 2021
(Expiration: Jun, 2034)
|
DEHNS
| |
| EP3160463B1 | Intermittent Dosing Of Mdm2 Inhibitor | NOVARTIS AG |
16 Jul, 2021
(Expiration: Jun, 2035)
|
BOEHRINGER INGELHEIM
| |
| EP2994108B1 | Oral Pharmaceutical Formulation | SIEGFRIED AG |
16 Jul, 2021
(Expiration: May, 2034)
|
EVONIK OPERATIONS
| |
| EP3107627B1 | Skin Cleansing Compositions Comprising Biodegradable Abrasive Particles | PROCTER AND GAMBLE CO |
16 Jul, 2021
(Expiration: Feb, 2035)
|
HENKEL
(and 1 more)
| |
| EP2597969B1 | Process For Obtaining Citrus Fiber From Citrus Pulp | CARGILL INC |
14 Jul, 2021
(Expiration: Jul, 2031)
|
HERBSTREITH & FOX PECTIN FABRIKEN
| |
| EP2651372B2 | Aerosol Device Having Two Compartments Including An Alcoholic Or Hydroalcoholic Hairstyling Composition, And Hairstyling Method | LOREAL SA |
13 Jul, 2021
(Expiration: Dec, 2031)
|
HENKEL
| |
| EP3290087B1 | Spray Compositions, Sprayable Products, And Methods Of Treating A Surface With The Same | PROCTER AND GAMBLE CO |
13 Jul, 2021
(Expiration: Aug, 2037)
|
HENKEL
| |
| EP2432333B1 | Human Milk Fortifier With High Protein And Long Chain Poly Unsaturated Fatty Acids For Improving Body Adipose Tissue Distribution | NUTRICIA NV |
12 Jul, 2021
(Expiration: May, 2030)
|
SOCIT DES PRODUITS NESTL
| |
| EP3566696B1 | Risperidone Sustained Release Microsphere Composition | SHANDONG LUYE PHARMACEUTICAL CO LTD |
07 Jul, 2021
(Expiration: Apr, 2032)
|
ALKERMES PHARMA IRELAND
| |
| EP2921160B1 | Stabilization Of Sunscreens In Cosmetic Compositions | UNILEVER PLC |
07 Jul, 2021
(Expiration: Mar, 2023)
|
BEIERSDORF
| |
| EP3294770B2 | Therapeutic And Diagnostic Methods For Cancer | F HOFFMANN LA ROCHE AG |
07 Jul, 2021
(Expiration: May, 2036)
|
GLAXOSMITHKLINE
(and 1 more)
| |
| EP3496657B1 | Blank And Method For Producing A Tooth Replacement Part | SIRONA DENTAL SYSTEMS GMBH |
07 Jul, 2021
(Expiration: Aug, 2037)
|
IVOCLAR VIVADENT
| |
| EP3230460B2 | Methods And Compositions For Selectively Eliminating Cells Of Interest | INDIVIDUAL |
06 Jul, 2021
(Expiration: Dec, 2035)
|
CAMULON
| |
| EP3003360B1 | High Potency Pancreatin Pharmaceutical Compositions | ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD |
06 Jul, 2021
(Expiration: Nov, 2034)
|
CAMULON
| |
| EP2885395B1 | Method For Freeze Drying A Bacteria-Containing Concentrate | CHR HANSEN AS |
06 Jul, 2021
(Expiration: Aug, 2033)
|
STRAWMAN
(and 2 more)
| |
| EP3558231B1 | Oil-In-Water Emulsion And Cosmetic Use Thereof | LOREAL SA |
02 Jul, 2021
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP3525755B1 | Preparation Of Nano-Sized Uv Absorbers | DSM IP ASSETS BV |
30 Jun, 2021
(Expiration: Oct, 2037)
|
BASF
| |
| EP3103443B1 | Method For Treating Primary Insomnia | NEURIM PHARMACEUTICALS 1991 LTD |
30 Jun, 2021
(Expiration: Aug, 2022)
|
GENERICS UK
(and 5 more)
| |
| EP3570884B1 | Subcutaneous Her2 Antibody Formulations | F HOFFMANN LA ROCHE AG |
30 Jun, 2021
(Expiration: Jan, 2038)
|
HOFFMANN EITLE
(and 3 more)
| |
| EP3533787B1 | Pyridone Compound As C-Met Inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO LTD |
30 Jun, 2021
(Expiration: Oct, 2037)
|
MERCK PATENT
| |
| EP3090756B1 | Formula Of Neuregulin Preparation | ZENSUN SHANGHAI SCIENCE AND TECHNOLOGY LTD |
30 Jun, 2021
(Expiration: Dec, 2034)
|
STRAWMAN
| |
| EP3428193B1 | Il2Rbeta/Common Gamma Chain Antibodies | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH SINGAPORE |
30 Jun, 2021
(Expiration: Aug, 2036)
|
TENEOBIO
| |
| EP3294850B1 | Very Long Chain Polyunsaturated Fatty Acids From Natural Oils | EPAX NORWAY AS |
29 Jun, 2021
(Expiration: May, 2036)
|
GOLDEN OMEGA
| |
| EP2516473B1 | Anionic Polysaccharides Functionalised By A Hydrophobic Acid Derivative | ADOCIA SAS |
29 Jun, 2021
(Expiration: Dec, 2030)
|
HAMMER
| |
| EP3171868B1 | Packaged Acetaminophen Injection Solution Preparation | TERUMO CORP |
29 Jun, 2021
(Expiration: Jul, 2034)
|
HOFFMANN EITLE
| |
| EP3507366B1 | Chemically Modified Single-Stranded Rna-Editing Oligonucleotides | PROQR THERAPEUTICS II BV |
25 Jun, 2021
(Expiration: Aug, 2037)
|
MARGARET DIXON
| |
| EP3244874B2 | Cosmetic Composition For Keratin Fibers And Manufacturing Method Thereof | LOREAL SA |
23 Jun, 2021
(Expiration: Dec, 2035)
|
HENKEL
| |
| EP1957110B8 | Process For Manufacturing Chewable Dosage Forms For Drug Delivery And Products Thereof | BAYER HEALTHCARE LLC |
22 Jun, 2021
(Expiration: Dec, 2026)
|
BOEHRINGER INGELHEIM ANIMAL HEALTH USA
| |
| EP3058987B1 | Composition For Providing A Film On Keratin Fibres | NOXELL CORP |
22 Jun, 2021
(Expiration: Feb, 2036)
|
HENKEL
| |
| EP3346973B1 | Process For Oxidative Dyeing Hair | KAO GERMANY GMBH |
22 Jun, 2021
(Expiration: Mar, 2036)
|
LOREAL
| |
| EP2793817B1 | Bleaching And Colouring Composition For Hair | KAO GERMANY GMBH |
22 Jun, 2021
(Expiration: Dec, 2032)
|
LOREAL
(and 1 more)
| |
| EP3390358B1 | Crystalline Eravacycline Bis-Hydrochloride | SANDOZ AG |
22 Jun, 2021
(Expiration: Jan, 2037)
|
TETRAPHASE PHARMACEUTICALS
| |
| EP3153526B1 | Antibodies Against Human Cd39 And Use Thereof For Inhibiting T Regulatory Cells Activity | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM |
21 Jun, 2021
(Expiration: Jan, 2029)
|
ABBVIE
(and 3 more)
| |
| EP3212200B1 | Use Of A Reverse-Transcriptase Inhibitor In The Prevention And Treatment Of Degenerative Diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS |
18 Jun, 2021
(Expiration: Oct, 2035)
|
SCHLICH
| |
| EP3117838B1 | Composition Containing Sophorolipid, Physiologically Active Substance And Oil And Fat, And Method Of Producing Said Composition | SARAYA CO LTD |
16 Jun, 2021
(Expiration: Mar, 2035)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3325013B2 | Stimulators And/Or Activators Of Soluble Guanylate Cyclase (Sgc) In Combination With An Inhibitor Of Neutral Endopeptidase (Nep Inhibitor) And/Or An Angiotensin Aii Antagonist And The Use Thereof | BAYER PHARMA AG |
16 Jun, 2021
(Expiration: Jul, 2036)
|
PAJARO
| |
| EP3155024B1 | Residence Structures And Related Methods | BRIGHAM AND WOMENS HOSPITAL INC |
15 Jun, 2021
(Expiration: Jun, 2035)
|
D YOUNG
| |
| EP2830584B1 | Composition Comprising (2,5-Diaminophenyl)Ethanol And A Cellulose Polymer Or Carboxylic Anionic Polymer In A Medium Rich In Fatty Substances, Dyeing Process And Device | LOREAL SA |
15 Jun, 2021
(Expiration: Mar, 2033)
|
HENKEL
| |
| EP3307239B1 | Formulations For Small Intestinal Delivery Of Rsv And Norovirus Antigens | VAXART INC |
15 Jun, 2021
(Expiration: Jun, 2036)
|
IOSBIO
| |
| EP3188709B1 | Transparent Cosmetic And Personal Care Compositions | UNILEVER PLC |
11 Jun, 2021
(Expiration: Aug, 2035)
|
HENKEL
| |
| EP3254695B1 | Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
09 Jun, 2021
(Expiration: May, 2033)
|
DR H ULRICH DRRIES
| |
| EP3278665B1 | Stable Pharmaceutical Composition And Methods Of Using Same | AMARIN PHARMACEUTICALS IRELAND LTD |
09 Jun, 2021
(Expiration: Apr, 2030)
|
ELKINGTON AND FIFE
| |
| EP3233258B1 | Two-Component Products In Bags For The Oxidative Dyeing Of Keratin Fibres | HENKEL AG AND CO KGAA |
09 Jun, 2021
(Expiration: Nov, 2035)
|
HAMMER
| |
| EP2698431B1 | Retention Of Antigen-Binding Molecules In Blood Plasma And Method For Modifying Immunogenicity | CHUGAI PHARMACEUTICAL CO LTD |
09 Jun, 2021
(Expiration: Mar, 2032)
|
J A KEMP
(and 1 more)
| |
| EP3270951B1 | Botulinum Neurotoxin-Specific Capture Agents, Compositions, And Methods Of Using And Making | CALIFORNIA INSTITUTE OF TECHNOLOGY CALTECH |
09 Jun, 2021
(Expiration: Mar, 2036)
|
MERZ PHARMA
| |
| EP3096785B1 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof | PFIZER INC |
09 Jun, 2021
(Expiration: Jan, 2035)
|
SK BIOSCIENCE
(and 2 more)
| |
| EP3308836B1 | Octocrylene-Free, Odour-Stable Sun Protection Agent | BEIERSDORF AG |
08 Jun, 2021
(Expiration: Jun, 2034)
|
BASF
(and 2 more)
| |
| EP2959892B1 | Enteric Coated Tablet | ZERIA PHARMACEUTICAL CO LTD |
08 Jun, 2021
(Expiration: Feb, 2034)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3095463B1 | Methods For Treating Progressive Multiple Sclerosis | F HOFFMANN LA ROCHE AG |
08 Jun, 2021
(Expiration: Sep, 2029)
|
POLPHARMA BIOLOGICS
(and 1 more)
| |
| EP2478907B1 | Methods And Compositions For Treating Cancer | JANSSEN ONCOLOGY INC |
03 Jun, 2021
(Expiration: Aug, 2027)
|
SYNTHON
(and 21 more)
| |
| EP2809773B1 | Process Of Modulating Man5 And/Or Afucosylation Content Of Glycoprotein Composition | DR REDDYS LABORATORIES LTD |
02 Jun, 2021
(Expiration: Jan, 2033)
|
BREUER
(and 4 more)
| |
| EP3323413B1 | Pharmaceutical Composition Containing Celecoxib And Tramadol | YOO YOUNG PHARM CO LTD |
02 Jun, 2021
(Expiration: Jun, 2036)
|
DEHMEL & BETTENHAUSEN PATENTANWLTE PARTMBB
| |
| EP3389789B1 | Composition Comprising The Combination Of Specific Alkoxysilanes And Of A Surfactant | LOREAL SA |
02 Jun, 2021
(Expiration: Dec, 2036)
|
HENKEL
| |
| EP3305285B1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC |
02 Jun, 2021
(Expiration: Sep, 2033)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 2 more)
| |
| EP2682099B1 | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | ARVEN ILAC SANAYI VE TICARET AS |
01 Jun, 2021
(Expiration: Jul, 2033)
|
ALFRED E TIEFENBACHER
(and 2 more)
| |
| EP2981822B1 | Compositions And Methods For Growth Factor Modulation | SCHOLAR ROCK INC |
01 Jun, 2021
(Expiration: May, 2034)
|
CHUGAI SEIYAKU KABUSHIKI KAISHA
| |
| EP3169320B1 | A New Treatment For Improving The Use Of Dietary Sugar For Energy Purposes | NUTRAVIS SRL |
01 Jun, 2021
(Expiration: Jul, 2035)
|
EUROMED
| |
| EP3065763B2 | Use Of Il-22 Dimer In Manufacture Of A Medicament For Intravenous Administration | EVIVE BIOTECHNOLOGY SHANGHAI LTD |
01 Jun, 2021
(Expiration: Nov, 2034)
|
STRAWMAN
| |
| EP3294333B1 | Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
31 May, 2021
(Expiration: May, 2036)
|
DR H ULRICH DRRIES
| |
| EP3220909B1 | Methods Of Modulating Drug Plasma Levels Using Erythrohydroxybupropion | ANTECIP BIOVENTURES II LLC |
31 May, 2021
(Expiration: May, 2035)
|
ELKINGTON AND FIFE
| |
| EP3348258B1 | Oral And Injectable Formulations Of Tetracycline Compounds | PARATEK PHARMACEUTICALS INC |
28 May, 2021
(Expiration: Mar, 2029)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3468568B1 | Human Platelet Lysate Derived Extracellular Vesicles For Use In Medicine | LYSATPHARMA GMBH |
28 May, 2021
(Expiration: Jun, 2037)
|
UNIVERSITT DUISBURG ESSEN
| |
| EP3388048B1 | Sunscreen With A Reduced Tendency To Stain Textiles Iii | BEIERSDORF AG |
26 May, 2021
(Expiration: Apr, 2035)
|
BASF
| |
| EP3332773B8 | Stabilized Modified Release Vitamin D Formulation And Method Of Administering Same | OPKO IRELAND GLOBAL HOLDINGS LTD |
26 May, 2021
(Expiration: Mar, 2034)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3169703B2 | Chimeric Antigen Receptor And Its Use | INDIVIDUAL |
26 May, 2021
(Expiration: Jul, 2035)
|
MARGARET DIXON
| |
| EP2382228B1 | Compositions And Methods Of Treating Inflammatory And Autoimmune Diseases | AMGEN INC |
26 May, 2021
(Expiration: Jan, 2030)
|
MERCK SHARP & DOHME
(and 3 more)
| |
| EP3370685B1 | Cosmetic Foam Made From An Emulsion Containing Glycerine And Alcohol | BEIERSDORF AG |
25 May, 2021
(Expiration: Oct, 2036)
|
HENKEL
| |
| EP3214956B1 | Solution Comprising Nicotine In Unprotonated From And Protonated Form | NICOVENTURES HOLDINGS LTD |
25 May, 2021
(Expiration: Nov, 2035)
|
PHILIP MORRIS PRODUCTS
| |
| EP3128993B1 | Mixtures Of Cosmetic Uv Absorbers | BASF SE |
25 May, 2021
(Expiration: Apr, 2035)
|
REGIMBEAU
| |
| EP3111974B1 | Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo | REGEN LAB SA |
18 May, 2021
(Expiration: Aug, 2027)
|
ESTAR
| |
| EP2970389B1 | Pharmaceutical Compositions | RHYTHM PHARMACEUTICALS INC |
18 May, 2021
(Expiration: Mar, 2034)
|
SANDOZ
| |
| EP2976101B1 | Method Of Treatment | GLAXOSMITHKLINE BIOLOGICALS SA |
18 May, 2021
(Expiration: Mar, 2034)
|
SANOFI PASTEUR
| |
| EP3209673B2 | Mixtures Of Hmos | GLYCOM AS |
17 May, 2021
(Expiration: Oct, 2035)
|
CHR HANSEN HMO
(and 1 more)
| |
| EP3445344B1 | Nicotine Delivery Product, Related Uses And Oral Dosage Forms, And Methods Of Production | FERTIN PHARMA AS |
17 May, 2021
(Expiration: Apr, 2036)
|
SIEGFRIED
| |
| EP3213750B1 | Combination Of Two Antivirals For Treating Hepatitis C | ABBVIE INC |
12 May, 2021
(Expiration: Mar, 2034)
|
GENERICS UK
| |
| EP3337478B1 | Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin | IPSEN BIOPHARM LTD |
12 May, 2021
(Expiration: Aug, 2036)
|
GENERICS UK
(and 1 more)
| |
| EP3409286B1 | Low Frequency Glatiramer Acetate Therapy | YEDA RESEARCH AND DEVELOPMENT CO LTD |
11 May, 2021
(Expiration: Aug, 2030)
|
SYNTHON
(and 1 more)
| |
| EP3068413B2 | A Feed Supplement And A Feed Composition Comprising Resin Acid Based Composition | FORCHEM OYJ |
06 May, 2021
(Expiration: Nov, 2034)
|
GREEN INNOVATION
| |
| EP3440063B1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH |
05 May, 2021
(Expiration: Apr, 2037)
|
AICURIS ANTI INFECTIVE CURES
| |
| EP3566695B1 | Treatment Of Coccidiosis With Intramuscular Triazine Compositions | CEVA SANTE ANIMALE SA |
05 May, 2021
(Expiration: Dec, 2033)
|
ELANCO
(and 1 more)
| |
| EP3203840B1 | Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INC |
05 May, 2021
(Expiration: Oct, 2035)
|
GENERICS UK
| |
| EP2872106B2 | Composite Pigment And Method For Preparing The Same | LOREAL SA |
05 May, 2021
(Expiration: Jul, 2032)
|
HENKEL
| |
| EP3054929B1 | Muco-Adhesive, Controlled Release Formulations Of Levodopa And/Or Esters Of Levodopa And Uses Thereof | IMPAX LABORATORIES LLC |
05 May, 2021
(Expiration: Oct, 2034)
|
LUIGI
| |
| EP2519300B1 | System For Treating Target Ti S Sue Within The Eustachian Tube | ACCLARENT INC |
05 May, 2021
(Expiration: Dec, 2030)
|
SPIGGLE & THEIS MEDIZINTECHNIK
| |
| EP3351267B1 | Vaccine For Protection Against Lawsonia Intracellularis | INTERVET INTERNATIONAL BV |
04 May, 2021
(Expiration: Apr, 2029)
|
CEVA SANTE ANIMALE
(and 1 more)
| |
| EP3368069B1 | Use Of Myostatin Inhibitors And Combination Therapies | SCHOLAR ROCK INC |
04 May, 2021
(Expiration: Jun, 2037)
|
GRUND
(and 1 more)
| |
| EP3298033B2 | Compositions And Methods For Tcr Reprogramming Using Fusion Proteins | TCR2 THERAPEUTICS INC |
04 May, 2021
(Expiration: May, 2036)
|
JONES DAY
| |
| EP2992891B1 | Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect | UCB PHARMA GMBH |
03 May, 2021
(Expiration: Jun, 2027)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3127551B1 | Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In Pigs | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
29 Apr, 2021
(Expiration: Dec, 2026)
|
ELANCO
(and 2 more)
| |
| EP2688587B2 | Salmonid Alphavirus Vaccine | INTERVET INTERNATIONAL BV |
29 Apr, 2021
(Expiration: Mar, 2032)
|
ELANCO
| |
| EP3328198B1 | Preservative System Based On Organic Acids | COLGATE PALMOLIVE CO |
29 Apr, 2021
(Expiration: Aug, 2035)
|
HENKEL
| |
| EP2688549B1 | Systems For Custom Coloration | COLORIGHT LTD |
29 Apr, 2021
(Expiration: Mar, 2032)
|
HENKEL
| |
| EP3052132B1 | Antibody Therapies For Human Immunodeficiency Virus (Hiv) | BETH ISRAEL DEACONESS MEDICAL CENTER INC |
29 Apr, 2021
(Expiration: Sep, 2034)
|
JAMES POOLE
| |
| EP3206716B1 | Use Of Cannabinoids In The Treatment Of Epilepsy | GW RESEARCH LTD |
29 Apr, 2021
(Expiration: Oct, 2035)
|
JAMES POOLE
| |
| EP3383385B2 | Melflufen Dosage Regimens For Cancer | ONCOPEPTIDES AB |
29 Apr, 2021
(Expiration: Dec, 2036)
|
LUIGI
(and 1 more)
| |
| EP3061448B1 | Composition Containing Eugenol As Active Ingredient For Preventing Or Treating Atopic Dermatitis | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
27 Apr, 2021
(Expiration: Oct, 2034)
|
BEIERSDORF
| |
| EP3397265B1 | Protein-Rich Enteral Nutritional Composition Containing A High Proportion Of Caseinates | EVEN SANTE INDUSTRIE SAS |
27 Apr, 2021
(Expiration: Dec, 2036)
|
LEIDESCHER
(and 1 more)
| |
| EP3113749B1 | Abrasive Skin Cleaning Products Ii | BEIERSDORF AG |
23 Apr, 2021
(Expiration: Feb, 2035)
|
DALLI WERKE
(and 1 more)
| |
| EP3057585B1 | Pegylated Drug-Linkers For Improved Ligand-Drug Conjugate Pharmacokinetics | SEATTLE GENETICS INC |
22 Apr, 2021
(Expiration: Oct, 2034)
|
EUROPEAN OPPOSITIONS
| |
| EP3241550B1 | (1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful Inflammations | GRUENENTHAL GMBH |
22 Apr, 2021
(Expiration: Nov, 2023)
|
GENERICS UK
(and 3 more)
| |
| EP3389612B1 | Composition Intended Especially For Shaving The Skin | LOREAL SA |
22 Apr, 2021
(Expiration: Dec, 2036)
|
HENKEL
| |
| EP3338784B1 | Human Milk Oligosaccharides For Modulating Inflammation | ABBOTT LABORATORIES |
22 Apr, 2021
(Expiration: Dec, 2031)
|
NUTRICIA
(and 1 more)
| |
| EP3226895B1 | Pharmaceutical Product With Increased Stability Comprising Immunoglobulins | CSL BEHRING AG |
22 Apr, 2021
(Expiration: Dec, 2035)
|
OCTAPHARMA
| |
| EP3145488B1 | Liquid Pharmaceutical Composition | FRESENIUS KABI DEUTSCHLAND GMBH |
22 Apr, 2021
(Expiration: May, 2035)
|
SAMSUNG BIOEPIS NL
(and 2 more)
| |
| EP2968172B8 | Stabilized Modified Release Vitamin D Formulation And Method Of Administring Same | EIRGEN PHARMA LTD |
21 Apr, 2021
(Expiration: Mar, 2034)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3469359B1 | Personalised Nutrient Dosing With On-Going Feedback Loop | BAZE LABS AG |
21 Apr, 2021
(Expiration: May, 2037)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3003316B1 | Combination Therapies For Cancer | GLAXOSMITHKLINE LLC |
21 Apr, 2021
(Expiration: May, 2034)
|
PAJARO
| |
| EP3528847B1 | High-Stability Packaged Solutions Of T4 Thyroid Hormone | ALTERGON SA |
21 Apr, 2021
(Expiration: Oct, 2037)
|
UNI PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES
| |
| EP3013306B1 | Nanocrystalline Zirconia And Methods Of Processing Thereof | IVOCLAR VIVADENT INC |
20 Apr, 2021
(Expiration: Jun, 2034)
|
M DEUTSCHLAND DE M INNOVATIVE PROPERTIES
| |
| EP3344227B1 | Composition Comprising At Least One Anionic Surfactant, At Least Two Particular Nonionic Surfactants, At Least One Amphoteric Surfactant And At Least One Particular Cationic Polymer | LOREAL SA |
19 Apr, 2021
(Expiration: Sep, 2036)
|
DALLI WERKE
| |
| EP3218504B1 | Tri-Segmented Arenaviruses As Vaccine Vectors | UNIVERSITE DE GENEVE |
16 Apr, 2021
(Expiration: Nov, 2035)
|
DR URSULA SPRENZEL
| |
| EP3209691B1 | Method And Compositions For Inducing Differentiation Of Myeloid Derived Suppressor Cell To Treat Cancer And Infectious Diseases | OSE IMMUNOTHERAPEUTICS SA |
15 Apr, 2021
(Expiration: Oct, 2035)
|
BYONDIS
| |
| EP3489211B1 | Improved Methods For Preparing Squalene | NOVARTIS AG |
15 Apr, 2021
(Expiration: May, 2031)
|
GLAXOSMITHKLINE BIOLOGICALS
| |
| EP3656765B1 | Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol | GRUENENTHAL GMBH |
15 Apr, 2021
(Expiration: Jul, 2031)
|
G L PHARMA
(and 5 more)
| |
| EP3021869B1 | Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Tigit Inhibitors | F HOFFMANN LA ROCHE AG |
15 Apr, 2021
(Expiration: Jul, 2034)
|
JAMES POOLE
(and 2 more)
| |
| EP3260117B8 | Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound | AMGEN INC |
14 Apr, 2021
(Expiration: Sep, 2024)
|
ARISTO PHARMA
(and 6 more)
| |
| EP3378900B1 | Pigment Powders | MERCK PATENT GMBH |
14 Apr, 2021
(Expiration: Mar, 2038)
|
BASF COLORS & EFFECTS
| |
| EP2768479B1 | Excipients For Nicotine-Containing Therapeutic Compositions | MODORAL BRANDS INC |
14 Apr, 2021
(Expiration: Oct, 2032)
|
PHILIP MORRIS PRODUCTS
| |
| EP3058937B1 | Composition For Forming A Film On Keratin Fibres | NOXELL CORP |
09 Apr, 2021
(Expiration: Feb, 2036)
|
HENKEL
| |
| EP2884999B1 | Method And Compositions For Cellular Immunotherapy | FRED HUTCHINSON CANCER RESEARCH CENTER |
09 Apr, 2021
(Expiration: Aug, 2033)
|
KNIG SZYNKA TILMANN VON RENESSE
| |
| EP2832858B1 | Method For Producing Steviol Glycoside | SUNTORY HOLDINGS LTD |
08 Apr, 2021
(Expiration: Mar, 2033)
|
GLEISS GROE SCHRELL UND PARTNER MBB
| |
| EP3152234B1 | Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes | CELLVAX |
08 Apr, 2021
(Expiration: Jun, 2035)
|
HOFFMANN EITLE
| |
| EP3215130B1 | Pharmaceutical Composition Comprising Bisoprolol And Perindoril | LABORATOIRES SERVIER SAS |
08 Apr, 2021
(Expiration: Nov, 2035)
|
KRKA
| |
| EP3348553B1 | Crystalline Forms Of An Androgen Receptor Modulator | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH |
08 Apr, 2021
(Expiration: Jun, 2033)
|
SAGITTARIUS CONSULTANTS
(and 1 more)
| |
| EP2340828B1 | Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor | NOVARTIS AG |
07 Apr, 2021
(Expiration: Nov, 2026)
|
SANOVEL ILA SANAYI VE TICARET ANONIM SIRKETI
(and 7 more)
| |
| EP2654736B1 | Novel Pharmaceutical Composition | NOVARTIS AG |
01 Apr, 2021
(Expiration: Dec, 2031)
|
GENERICS UK
(and 1 more)
| |
| EP3515583B1 | Fluidised Bed System | HUETTLIN GMBH |
01 Apr, 2021
(Expiration: Jul, 2037)
|
GLATT GESELLSCHAFT MIT BESCHRNKTER HAFTUNG
| |
| EP3337447B2 | Process For Treating Keratin Fibres With An Alkoxysilane Polymer Bearing A Nucleophilic Group And An Activated (Thio)Ester | LOREAL SA |
01 Apr, 2021
(Expiration: Aug, 2036)
|
HENKEL
| |
| EP3215223B1 | Buprenorphine Dosing Regimens | INDIVIOR UK LTD |
30 Mar, 2021
(Expiration: Nov, 2035)
|
ELKINGTON AND FIFE
| |
| EP3206987B1 | Nanoparticles For Photodynamic Therapy, X-Ray Induced Photodynamic Therapy, Radiotherapy, Chemotherapy, Immunotherapy, And Any Combination Thereof | UNIVERSITY OF CHICAGO |
30 Mar, 2021
(Expiration: Oct, 2035)
|
PLOUGMANN VINGTOFT
| |
| EP1901620B1 | Phosphatidylserine Enriched Milk Fractions For The Formulation Of Functional Foods | ARLA FOODS AMBA |
29 Mar, 2021
(Expiration: May, 2026)
|
FRIESLANDCAMPINA NEDERLAND
| |
| EP3454672B1 | Fermented Infant Formula | NUTRICIA NV |
29 Mar, 2021
(Expiration: May, 2037)
|
SOCIT DES PRODUITS NESTL
| |
| EP3461895B1 | Modulation Of Ube3A-Ats Expression | BAYLOR COLLEGE OF MEDICINE |
26 Mar, 2021
(Expiration: Jun, 2033)
|
F HOFFMANN LA ROCHE
| |
| EP3144318B1 | Recombinant Fsh Including Alpha 2,3- And Alpha 2,6-Sialylation | FERRING BV |
25 Mar, 2021
(Expiration: Apr, 2029)
|
ARES TRADING
| |
| EP3265051B1 | Aqueous Sun-Related Cosmetic Composition Free Of Surfactants | NAOS LES LABORATOIRES |
24 Mar, 2021
(Expiration: Mar, 2036)
|
BASF
(and 1 more)
| |
| EP2579835B1 | Compositions For Treating Skin | PROCTER AND GAMBLE CO |
24 Mar, 2021
(Expiration: Jun, 2031)
|
HENKEL
| |
| EP2997134B1 | Human Application Of Engineered Chimeric Antigen Receptor (Car) T-Cells | UNIVERSITY OF TEXAS SYSTEM |
24 Mar, 2021
(Expiration: May, 2034)
|
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
| |
| EP3409272B1 | Pharmaceutical Composition Comprising Eltrombopag Olamine, Reducing Sugar, And Polymeric Binder | ALFRED E TIEFENBACHER GMBH AND CO KG |
23 Mar, 2021
(Expiration: Apr, 2038)
|
BLLE DR
| |
| EP3085386B1 | Method For Inhibiting Bone Resorption | AMGEN INC |
23 Mar, 2021
(Expiration: Sep, 2028)
|
JAMES POOLE
| |
| EP3228299B1 | Novel Sunscreen Composition With A Reduced Textile Staining | BEIERSDORF AG |
23 Mar, 2021
(Expiration: Mar, 2037)
|
LOREAL
| |
| EP3264917B1 | Rebaudioside-D Containing Sweetener Compositions | HEARTLAND CONSUMER PRODUCTS LLC |
22 Mar, 2021
(Expiration: Mar, 2036)
|
BUDDE SCHOU
| |
| EP3380198B1 | Cosmetic Composition Comprising At Least One Powder Having A Low Thermal Conductivity | CHANEL PARFUMS BEAUTE SAS |
22 Mar, 2021
(Expiration: Nov, 2036)
|
TRSCH
| |
| EP2099453B1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH |
19 Mar, 2021
(Expiration: Oct, 2027)
|
ZENTIVA GROUP
(and 8 more)
| |
| EP3219328B1 | Human Anti-Il-23 Antibodies, Compositions, Method And Uses | JANSSEN BIOTECH INC |
17 Mar, 2021
(Expiration: Dec, 2026)
|
BOEHRINGER INGELHEIM PHARMA
(and 1 more)
| |
| EP3068403B1 | Methods Of Treatment Of Ocular Conditions With A Sustained Drug Delivery Implant | ALLERGAN INC |
16 Mar, 2021
(Expiration: Nov, 2034)
|
DF MP DRRIES FRANK MOLNIA & POHLMAN
| |
| EP2822568B1 | Uses Of Casein Compositions | FONTERRA COOPERATIVE GROUP LTD |
16 Mar, 2021
(Expiration: Mar, 2033)
|
NUTRICIA
| |
| EP2493466B1 | Novel Antitumoral Use Of Cabazitaxel | SANOFI MATURE IP |
10 Mar, 2021
(Expiration: Oct, 2030)
|
ACCORD HEALTHCARE
(and 11 more)
| |
| EP2328553B1 | Corticosteroids For The Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract | UNIVERSITY OF CALIFORNIA |
10 Mar, 2021
(Expiration: Nov, 2028)
|
AECHTER
| |
| EP3311791B1 | Ethanol Sunscreen Composition With A Reduced Likelihood Of Discolouring Textiles | BEIERSDORF AG |
10 Mar, 2021
(Expiration: Oct, 2037)
|
LOREAL
(and 2 more)
| |
| EP2793833B1 | Topical Oil Composition For The Treatment Of Fungal Infections | VYOME THERAPEUTICS LTD |
04 Mar, 2021
(Expiration: Dec, 2032)
|
HENKEL
(and 2 more)
| |
| EP3453387B1 | Dosage Regimen For A S1P Receptor Agonist | NOVARTIS AG |
03 Mar, 2021
(Expiration: Dec, 2029)
|
LABORATORIOS LICONSA
(and 2 more)
| |
| EP3354253B1 | Use Of Diethylaminohydroxybenzoylhexylbenzoate In Cosmetic Sunscreening Compositions | BEIERSDORF AG |
03 Mar, 2021
(Expiration: Jan, 2038)
|
STADA ARZNEIMITTEL
(and 2 more)
| |
| EP2658549B1 | Methods For Reducing The Incidence Of Oxidative Stress Using Human Milk Oligosaccharides, Vitamin C And Anti-Inflammatory Agents | ABBOTT LABORATORIES |
02 Mar, 2021
(Expiration: Dec, 2031)
|
SOCIT DES PRODUITS NESTL
(and 1 more)
| |
| EP3204047B1 | Calcifediol Soft Capsules | FAES FARMA SA |
01 Mar, 2021
(Expiration: Feb, 2036)
|
DSM NUTRITIONAL PRODUCTS
(and 2 more)
| |
| EP3459356B1 | Improved Method For Producing Blood Meal | TESSENDERLO GROUP NV |
01 Mar, 2021
(Expiration: Jan, 2038)
|
HAARSLEV INDUSTRIES
(and 3 more)
| |
| EP3093295B1 | Il-15 Heterogeneous Dimer Protein And Uses Thereof | JIANGSU HENGRUI MEDICINE CO LTD |
01 Mar, 2021
(Expiration: Dec, 2034)
|
MARGARET DIXON
| |
| EP2985016B1 | Dental Composite Material Having Stable Pasty Property | SHOFU INC |
26 Feb, 2021
(Expiration: Jul, 2035)
|
IVOCLAR VIVADENT
(and 1 more)
| |
| EP2982361B1 | Composite Material Having Reduced Degradation Of Pasty Property | SHOFU INC |
26 Feb, 2021
(Expiration: Jul, 2035)
|
IVOCLAR VIVADENT
(and 1 more)
| |
| EP1591105B1 | Use Of Antioxidants For The Preparation Of Pharmaceutical Or Cosmetic Compositions For Protecting The Skin From Damages By Infrared-Radiations | STADA ARZNEIMITTEL AG |
26 Feb, 2021
(Expiration: Mar, 2025)
|
MERCK PATENT
(and 5 more)
| |
| EP2233127B1 | Use Of Antioxidants For The Preparation Of Pharmaceutical Or Cosmetic Compositions For Protecting The Skin From Damages By Infrared-Radiations | STADA ARZNEIMITTEL AG |
26 Feb, 2021
(Expiration: Mar, 2025)
|
MERCK PATENT
(and 7 more)
| |
| EP2723354B3 | Compositions, Uses, And Preparation Of Platelet Lysates | EMORY UNIVERSITY |
26 Feb, 2021
(Expiration: Jun, 2032)
|
PILLER
| |
| EP3443979B1 | Il-2 Dosage Regimen For Treating Systemic Lupus Erythematosus | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP |
26 Feb, 2021
(Expiration: Mar, 2032)
|
STRAWMAN
| |
| EP3320919B1 | Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
25 Feb, 2021
(Expiration: Dec, 2026)
|
ELANCO
(and 1 more)
| |
| EP2646003B1 | Rapidly Dispersing Granules, Orally Disintegrating Tablets And Methods | ADARE PHARMACEUTICALS INC |
23 Feb, 2021
(Expiration: Dec, 2031)
|
DR FALK PHARMA
| |
| EP3256101B1 | Solid Anhydrous Cosmetic Composition, Preparation Process, Cosmetic Treatment Processes And Associated Kit | LOREAL SA |
20 Feb, 2021
(Expiration: Dec, 2035)
|
HENKEL
| |
| EP2653162B1 | Methods Of Administering Fluvoxamine Therapy | INTERMUNE INC |
19 Feb, 2021
(Expiration: Dec, 2030)
|
ALFRED E TIEFENBACHER
(and 3 more)
| |
| EP3346975B1 | Process For Semipermanent Straightening And Dyeing Hair | KAO GERMANY GMBH |
19 Feb, 2021
(Expiration: Mar, 2036)
|
HENKEL
| |
| EP3086863B2 | Cosmetic Compositions And Methods Providing Enhanced Penetration Of Skin Care Actives | PROCTER AND GAMBLE CO |
19 Feb, 2021
(Expiration: Dec, 2034)
|
HENKEL
(and 1 more)
| |
| EP2815752B1 | Oral Pharmaceutical Composition | TAIHO PHARMACEUTICAL CO LTD |
19 Feb, 2021
(Expiration: Feb, 2033)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3490526B1 | Isotonic Crystalloid Aqueous Solution | INDIVIDUAL |
12 Feb, 2021
(Expiration: Jul, 2037)
|
LABORATOIRES QUINTON
| |
| EP3135275B1 | Pharmaceutical Composition Capable Of The Incorporation Of Lenalidomide In Various Crystalline Modifications | JSC GRINDEKS |
11 Feb, 2021
(Expiration: Aug, 2035)
|
BACHELIN
(and 2 more)
| |
| EP3253410B1 | A Vaccine For Use Against Subclinical Lawsonia Infection In A Pig | INTERVET INTERNATIONAL BV |
08 Feb, 2021
(Expiration: Feb, 2036)
|
BOEHRINGER INGELHEIM VETMEDICA
(and 1 more)
| |
| EP3223834B2 | Probiotic And Prebiotic Compositions, And Methods Of Use Thereof For Modulation Of The Microbiome | EVELO BIOSCIENCES INC |
08 Feb, 2021
(Expiration: Nov, 2035)
|
HGF
| |
| EP3253409B1 | A Vaccine For Use Against Subclinical Lawsonia Infection In A Pig | INTERVET INTERNATIONAL BV |
05 Feb, 2021
(Expiration: Feb, 2036)
|
CEVA SANTE ANIMALE
(and 1 more)
| |
| EP3057612B1 | Method Of Obtaining Thermostable Dried Vaccine Formulations | MERCK SHARP AND DOHME LLC |
05 Feb, 2021
(Expiration: Oct, 2034)
|
GLAXO GROUP
| |
| EP2204157B1 | Two-Pack Hairdye Composition | KAO CORP |
05 Feb, 2021
(Expiration: Oct, 2027)
|
HENKEL
| |
| EP3019610B1 | Methods For Performing Antisense Oligonucleotide-Mediated Exon Skipping In The Retina Of A Subject In Need Thereof | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP |
05 Feb, 2021
(Expiration: Jul, 2034)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP2797581B1 | Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione | AMGEN EUROPE GMBH |
05 Feb, 2021
(Expiration: Dec, 2032)
|
KRKA
(and 2 more)
| |
| EP3389691B1 | Cyclic Ntcp-Targeting Peptides And Their Uses As Entry Inhibitors | UNIVERSITAET HEIDELBERG |
05 Feb, 2021
(Expiration: Dec, 2036)
|
MARGARET DIXON
| |
| EP2641917B1 | Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) | AMGEN INC |
05 Feb, 2021
(Expiration: Aug, 2028)
|
SANOFI
| |
| EP2411048B1 | Adjuvanting Meningococcal Factor H Binding Protein | GLAXOSMITHKLINE BIOLOGICALS SA |
05 Feb, 2021
(Expiration: Mar, 2030)
|
SANOFI PASTEUR
| |
| EP3062798B1 | Modified Rna With Decreased Immunostimulatory Properties | CUREVAC AG |
05 Feb, 2021
(Expiration: Oct, 2034)
|
WEICKMANN & WEICKMANN PARTMBB
(and 1 more)
| |
| EP2506850B1 | Methods Of Administering Pirfenidone Therapy | INTERMUNE INC |
03 Feb, 2021
(Expiration: Dec, 2030)
|
AERA
(and 5 more)
| |
| EP3528900B1 | Compressed Hair Spray | UNILEVER PLC |
03 Feb, 2021
(Expiration: Oct, 2037)
|
LOREAL
| |
| EP3115047B1 | Debility Preventative | AJINOMOTO CO INC |
01 Feb, 2021
(Expiration: Mar, 2035)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP3178483B1 | Composition For Inducing Proliferation Or Accumulation Of Regulatory T Cells | UNIVERSITY OF TOKYO NUC |
29 Jan, 2021
(Expiration: Jun, 2031)
|
POTTER CLARKSON
(and 3 more)
| |
| EP3313372B1 | Packaged Silicone Lubricated Condom That Provides Sensation | LIFESTYLES HEALTHCARE PTE LTD |
29 Jan, 2021
(Expiration: May, 2036)
|
RECKITT BENCKISER HEALTH
| |
| EP3552613B1 | Composition For Inducing Proliferation Or Accumulation Of Regulatory T Cells | UNIVERSITY OF TOKYO NUC |
29 Jan, 2021
(Expiration: Jun, 2031)
|
STRAWMAN
(and 1 more)
| |
| EP3539548B1 | Composition For Inducing Proliferation Or Accumulation Of Regulatory Cells | UNIVERSITY OF TOKYO NUC |
29 Jan, 2021
(Expiration: Jun, 2031)
|
STRAWMAN
(and 3 more)
| |
| EP3558224B1 | Use Of Chelating Agents For Improving Color Stability Of Resorcinol | UNILEVER PLC |
28 Jan, 2021
(Expiration: Nov, 2037)
|
HENKEL
| |
| EP2341905B2 | Sustained Release Formulations Using Non-Aqueous Carriers | AMYLIN PHARMACEUTICALS LLC |
28 Jan, 2021
(Expiration: Sep, 2029)
|
INSTONE
| |
| EP3205334B1 | Method And Composition For Treating Ocular Hypertension And Glaucoma | ASAHI GLASS CO LTD |
26 Jan, 2021
(Expiration: May, 2029)
|
COOKE
| |
| EP3085683B1 | Bio-Derived 1,3-Propanediol As Natural And Non Irritating Solvents For Biomass-Derived Extracts, Fragrance Concentrates, And Oils | DUPONT TATE AND LYLE BIO PRODUCTS CO LLC |
26 Jan, 2021
(Expiration: Feb, 2027)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3260110B1 | Aerosol Hairspray Product For Styling And/Or Shaping Hair | PROCTER AND GAMBLE CO |
22 Jan, 2021
(Expiration: Dec, 2031)
|
HENKEL
(and 1 more)
| |
| EP3287123B1 | Aqueous Pharmaceutical Formulation Of Tapentadol For Oral Administration | GRUENENTHAL GMBH |
22 Jan, 2021
(Expiration: Mar, 2032)
|
LABOMED PHARMACEUTICAL COMPAMY
| |
| EP3421092B1 | Anti-Regurgitation Composition Preserving Gut Motility | UNITED PHARMACEUTICALS SA |
22 Jan, 2021
(Expiration: May, 2034)
|
NUTRICIA
| |
| EP3280416B1 | Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters | JANSSEN PHARMACEUTICALS INC |
22 Jan, 2021
(Expiration: Mar, 2036)
|
STADA ARZNEIMITTEL
(and 7 more)
| |
| EP3111916B1 | Use Of Charged Surfactants For Reducing Textile Staining By Antiperspirants | BEIERSDORF AG |
22 Jan, 2021
(Expiration: Feb, 2030)
|
UNILEVER UNILEVER
(and 1 more)
| |
| EP3317281B1 | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1 -(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide | ACERTA PHARMA BV |
21 Jan, 2021
(Expiration: Jul, 2036)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3461478B1 | Swallowable Drug Delivery Device | RANI THERAPEUTICS LLC |
21 Jan, 2021
(Expiration: Dec, 2030)
|
NOVO NORDISK
| |
| EP2349321B1 | Annexin And Its Use To Treat Inflammatory Disorders | LONDON HEALTH SCIENCES CENTRE RESEARCH INC |
21 Jan, 2021
(Expiration: Oct, 2029)
|
STRAWMAN
| |
| EP2683382B1 | Dosing Regimens For The Treatment Of Fabry Disease | AMICUS THERAPEUTICS INC |
21 Jan, 2021
(Expiration: Mar, 2032)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP2651442B1 | Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer | UNIVERSITY OF MARYLAND AT BALTIMORE |
20 Jan, 2021
(Expiration: Dec, 2031)
|
GEMOAB
(and 1 more)
| |
| EP2830573B1 | Process For Bleaching Keratin Fibres | LOREAL SA |
20 Jan, 2021
(Expiration: Mar, 2033)
|
HENKEL
| |
| EP3134095B1 | Improved Methods For Manufacturing Adoptive Cell Therapies | BLUEBIRD BIO INC |
19 Jan, 2021
(Expiration: Apr, 2035)
|
DEHNS
(and 2 more)
| |
| EP2968254B1 | Methods Of Treating Lung Cancer | ABRAXIS BIOSCIENCE LLC |
19 Jan, 2021
(Expiration: Mar, 2034)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3336082B1 | Cleavable Lipids | TRANSLATE BIO INC |
15 Jan, 2021
(Expiration: Jun, 2032)
|
DILG
(and 1 more)
| |
| EP3045164B1 | Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes | NOVARTIS AG |
15 Jan, 2021
(Expiration: Jun, 2030)
|
GENERICS UK
| |
| EP2945628B1 | Androgen Receptor Modulator And Uses Thereof | ARAGON PHARMACEUTICALS INC |
15 Jan, 2021
(Expiration: Jan, 2034)
|
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
(and 3 more)
| |
| EP3137070B1 | Krill Oil Preparations And Their Uses | AKER BIOMARINE ANTARCTIC AS |
15 Jan, 2021
(Expiration: Apr, 2035)
|
RIMFROST
| |
| EP3302715B1 | Composition Comprising A Particular Anionic Associative Polymer, A Particular Fixing Polymer And A Particular Anionic Polymer | LOREAL SA |
14 Jan, 2021
(Expiration: Jun, 2036)
|
HENKEL
| |
| EP2782588B1 | Methods And Compositions For The Treatment Of Diabetes And Related Symptoms | EMMAUS MEDICAL INC |
14 Jan, 2021
(Expiration: Nov, 2032)
|
JAMES POOLE
| |
| EP3478807B1 | Lubricating Oil | GREEN FRIX |
14 Jan, 2021
(Expiration: Jun, 2037)
|
MICROS CHANGSHU LUBRICATION TECHNOLOGY
| |
| EP3307290B1 | Dietary Supplement | SOCIETE DES PRODUITS NESTLE SA |
13 Jan, 2021
(Expiration: Jun, 2036)
|
FRIESLANDCAMPINA NEDERLAND
(and 2 more)
| |
| EP2978419B1 | Compositions For Improving Cell Viability And Methods Of Use Thereof | AMYLYX PHARMACEUTICALS INC |
11 Jan, 2021
(Expiration: Feb, 2034)
|
BRUSCHETTINI
(and 1 more)
| |
| EP3003058B2 | Stevia Extract Containing Selected Steviol Glycosides As Flavor, Salty And Sweetness Profile Modifier | PURECIRCLE USA INC |
11 Jan, 2021
(Expiration: Jun, 2034)
|
CARGILL
| |
| EP2395983B1 | Pharmaceutical Composition Comprising A Sglt2 Inhibitor, A Dpp-Iv Inhibitor And Optionally A Further Antidiabetic Agent And Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
11 Jan, 2021
(Expiration: Feb, 2030)
|
GENERICS UK
(and 2 more)
| |
| EP2785828B1 | Human-Derived Bacteria That Induce Proliferation Or Accumulation Of Regulatory T Cells | SCHOOL CORP AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION |
11 Jan, 2021
(Expiration: Nov, 2032)
|
HGF
| |
| EP3087098B1 | Anti-Vista Antibodies And Fragments | JANSSEN PHARMACEUTICA NV |
09 Jan, 2021
(Expiration: Dec, 2034)
|
REGIMBEAU
(and 1 more)
| |
| EP3423028B1 | Method For The Production Of Scent Capsules With Improved Surfactant Stablity | SYMRISE AG |
08 Jan, 2021
(Expiration: Feb, 2036)
|
FIRMENICH
(and 1 more)
| |
| EP2866825B1 | Use Of Long-Acting Glp-1 Peptides | NOVO NORDISK AS |
08 Jan, 2021
(Expiration: Jun, 2033)
|
GALENICUM HEALTH SLU
(and 2 more)
| |
| EP2961775B1 | Pharmaceutical Compositions With Enhanced Performance And Improved Processability | HERCULES LLC |
08 Jan, 2021
(Expiration: Feb, 2034)
|
SHIN ETSU CHEMICAL
| |
| EP2399588B1 | Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase | IONIS PHARMACEUTICALS INC |
07 Jan, 2021
(Expiration: Jan, 2022)
|
GILEAD SCIENCES
| |
| EP2234963B1 | Controlled Release Formulations Of Levodopa And Uses Thereof | IMPAX LABORATORIES LLC |
07 Jan, 2021
(Expiration: Dec, 2028)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3481363B1 | Personal Cleansing Compositions | UNILEVER PLC |
06 Jan, 2021
(Expiration: Jul, 2037)
|
HENKEL
|